Digital Therapeutics Market Synopsis
The Global Digital Therapeutics market size was reasonably estimated to be approximately USD 6050 Million in 2023 and is poised to generate revenue over USD 12880 Million by the end of 2030, projecting a CAGR of around 20.41% from 2023 to 2030.
Digital therapeutics refers to the use of digital technologies, like smartphone apps, wearable devices, and software programs, to provide evidence-based therapeutic interventions for treating and managing various health conditions.
- Digital therapeutics involve interactive tools and platforms that offer educational content, behaviour-change techniques, and real-time monitoring of a patient's health data. They can be used alongside traditional medical treatments to enhance their effectiveness or as independent interventions.
- The goal of digital therapeutics is to provide personalized, accessible, and cost-effective solutions for patients. Examples include cognitive behavioural therapy apps for mental health, mobile applications for managing diabetes, or virtual reality programs for pain management. These interventions are developed based on scientific evidence and undergo rigorous testing to ensure their safety and efficacy.
- In summary, digital therapeutics utilize technology to deliver therapeutic interventions that improve health outcomes, empower patients to actively manage their conditions, and potentially reduce the need for more invasive or costly treatments.
Top Key Players Involved Are:
"Omada Health Inc. (US), ResMed (US), Pear Therapeutics Inc. (US), Solera Network (US), Akili Interactive Labs Inc. (US), Better Therapeutics LLC (US), Biofourmis (US), Click Therapeutics Inc. (US), Naturalcycles Nordic AB (Sweden), NuvoAir AB (Sweden), Welldoc’s Bluestar (US), Happify Inc. (US), Limbix Health Inc. (US), Voluntis (US), Xealth (US), Biobeat (Israel), Kaia Health (US), Ginger (US), Propeller Health (US), Hinge Health Inc. (US) And Other Major Key Players."
The Digital Therapeutics Market Trend Analysis
Increasing Prevalence of Chronic Diseases
- Long-term health conditions, such as diabetes, cardiovascular disorders (including heart disease and stroke), and mental health illnesses, are ailments that persist over a significant period and frequently necessitate continuous treatment. These diseases are progressively more prevalent and are imposing substantial challenges on individuals and healthcare systems globally.
- Chronic diseases are becoming increasingly common due to factors such as unhealthy lifestyle choices, ageing populations, and genetic predispositions. These conditions have a substantial impact on individuals' quality of life and necessitate ongoing monitoring, medication, and adjustments to one's lifestyle for effective management.
- Digital therapeutics leverage technology to enhance health outcomes, promote patient engagement, and decrease the reliance on invasive or costly interventions. These interventions provide convenience and accessibility by delivering healthcare support directly to individuals via smartphones or other digital devices. The primary objective is to simplify the management of chronic diseases, improve efficacy, and increase accessibility, thereby fostering improved overall health and well-being.
Personalized Medicine & Targeted Interventions
- Personalized medicine involves customizing medical treatments according to individual patients' distinct characteristics, including their genetic composition, lifestyle choices, and medical background. Digital therapeutics, by utilizing advanced data collection and analysis capabilities, present a promising pathway for implementing personalized medicine.
- Digital therapeutics can collect data from patients using a variety of sources such as wearable devices, smartphone apps, and self-reported information. This data can offer valuable insights into a person's health condition, behaviours, and responses to treatment. Through careful analysis of this data, digital therapeutics can detect patterns and tailor interventions to cater to the unique requirements of each patient.
- Digital therapeutics can enhance treatment outcomes by offering targeted interventions that address specific symptoms or behaviours. For instance, in a mental health program, digital therapeutics can provide tailored cognitive behavioural therapy techniques that effectively tackle anxiety or depression symptoms. This focused approach ensures more efficient and successful treatments, ultimately leading to better patient outcomes.
- Digital therapeutics offer personalized and targeted interventions, enabling a precision medicine approach that optimizes treatment plans, enhances patient engagement, and potentially improves health outcomes.
Segmentation Analysis Of The Digital Therapeutics Market
Digital Therapeutics market segments cover the Type, Application, Sales Channel and End-User. By Type, the software segment is Anticipated to Dominate the Market Over the Forecast period.
- Digital Therapeutics software is a type of healthcare application that provides evidence-based interventions for preventing, managing, and treating medical conditions. It runs on digital devices like smartphones, tablets, or computers, enabling patients to conveniently and remotely access therapeutic interventions. These applications are scientifically developed and can be used alongside traditional medical treatments or as independent therapies.
- Digital Therapeutics software employs a blend of behaviour change techniques, health monitoring tools, educational content, and interactive features to engage and assist patients in attaining targeted health objectives. These objectives encompass medication adherence, lifestyle adjustments, symptom control, and overall disease management. The software monitors patient progress, offers personalized recommendations, and provides real-time feedback to both patients and healthcare providers.
- Digital Therapeutics software provides numerous benefits, such as improved accessibility and scalability, along with the ability to deliver personalized interventions to patients. It holds the potential to enhance patient engagement, adherence, and overall health outcomes while also reducing healthcare costs. However, it is crucial to subject Digital Therapeutics software to thorough clinical validation to ensure it meets safety, efficacy, and regulatory standards before integration into a patient's treatment plan.
Regional Analysis of The Digital Therapeutics Market
North America is Expected to Dominate the Market Over the Forecast Period.
- The North American market for digital therapeutics has witnessed substantial growth and acceptance in recent times. With its advanced healthcare infrastructure, favourable reimbursement policies, and high prevalence of chronic diseases, North America, including countries like the United States and Canada, stands as a crucial region for Digital Therapeutics.
- Digital Therapeutics solutions are gaining traction in North America, with their application spanning diverse therapeutic areas such as diabetes management, mental health, cardiovascular diseases, respiratory disorders, and obesity. The region's focus on patient-centred care, rising healthcare costs, and the demand for innovative treatment options have fostered the acceptance of Digital Therapeutics as a complementary approach alongside conventional healthcare methods.
- North America's Digital Therapeutics market is thriving due to the presence of pharmaceutical companies, digital health startups, and supportive regulatory bodies. Advancements in technology, increased investments, and growing awareness among healthcare professionals and patients are driving the expansion of Digital Therapeutics, revolutionizing healthcare delivery in the region.
Covid-19 Impact Analysis On Digital Therapeutics Market
- The digital therapeutics market has experienced a dual impact from the COVID-19 pandemic. On the positive side, the demand for remote healthcare solutions and the necessity of maintaining social distancing measures have fast-tracked the adoption of digital health, including Digital Therapeutics. The pandemic has underscored the significance of remote monitoring, virtual care, and self-management tools, resulting in a surge of interest and investment in Digital Therapeutics. The Digital Therapeutics market has encountered hurdles during the pandemic, including disruptions in healthcare systems, regulatory obstacles, and economic constraints. These challenges have affected the adoption and implementation of Digital Therapeutics solutions, as well as the introduction of new products.
- The COVID-19 pandemic has both provided growth opportunities and presented challenges to the Digital Therapeutics market. Factors such as disruptions, economic constraints, and regulatory changes will determine the long-term impact on the market. The ability of Digital Therapeutics companies to showcase the value and overcome implementation barriers will also play a significant role.
Top Key Players Covered in The Digital Therapeutics Market
- Omada Health Inc. (US)
- ResMed (US)
- Pear Therapeutics Inc. (US)
- Solera Network (US)
- Akili Interactive Labs Inc. (US)
- Better Therapeutics LLC (US)
- Biofourmis (US)
- Click Therapeutics Inc. (US)
- Naturalcycles Nordic AB (Sweden)
- NuvoAir AB (Sweden)
- Welldoc’s Bluestar (US)
- Happify Inc. (US)
- Limbix Health Inc. (US)
- Voluntis (US)
- Xealth (US)
- Biobeat (Israel)
- Kaia Health (US)
- Ginger (US)
- Propeller Health (US)
- Hinge Health Inc. (US) and Other Major Players
Key Industry Developments in the Digital Therapeutics Market
In January 2023, Omada Health and Castell partnered to expand access to Omada's Diabetes Prevention Program and Diabetes Program for patients and caregivers at Intermountain Healthcare's Utah Medical Group. Castell helped identify eligible patients and offered them the option to enroll in the Omada programs through proactive outreach by care coordinators and healthcare providers.
In November 2023, ResMed Completed the Acquisition of MEDIFOX DAN, a German Leader in Out-of-Hospital Care Management Software Solutions. For a wide variety of out-of-hospital care providers.
Global Digital Therapeutics Market
|
Base Year:
|
2022
|
Forecast Period:
|
2023-2030
|
Historical Data:
|
2016 to 2021
|
Market Size in 2022:
|
USD 6050 Mn.
|
Forecast Period 2023-30 CAGR:
|
20.41%
|
Market Size in 2030:
|
USD 12880 Mn.
|
Segments Covered:
|
By Type
|
|
By Application
|
- Mental Health
- Diabetes Management
- Cardiovascular Disease
- Respiratory Disorders
- Obesity Management
- Neurological Disorders
- Others
|
By Sales Channel
|
|
By End Users
|
- Patients
- Healthcare Providers
- Employers
- Insurers/Payers
- Others
|
By Region
|
- North America (U.S., Canada, Mexico)
- Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
- Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
- Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New Zealand, Rest of APAC)
- Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
- South America (Brazil, Argentina, Rest of SA)
|
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
3.3 By Sales Channel
3.4 By End-user
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Digital Therapeutics Market by Type
5.1 Digital Therapeutics Market Overview Snapshot and Growth Engine
5.2 Digital Therapeutics Market Overview
5.3 Device
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2016-2030F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Device: Geographic Segmentation
5.4 Software
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2016-2030F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Software: Geographic Segmentation
5.5 Hybrid
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2016-2030F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Hybrid: Geographic Segmentation
Chapter 6: Digital Therapeutics Market by Application
6.1 Digital Therapeutics Market Overview Snapshot and Growth Engine
6.2 Digital Therapeutics Market Overview
6.3 Mental Health
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2016-2030F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Mental Health: Geographic Segmentation
6.4 Diabetes Management
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2016-2030F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Diabetes Management: Geographic Segmentation
6.5 Cardiovascular Disease
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2016-2030F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Cardiovascular Disease: Geographic Segmentation
6.6 Respiratory Disorders
6.6.1 Introduction and Market Overview
6.6.2 Historic and Forecasted Market Size (2016-2030F)
6.6.3 Key Market Trends, Growth Factors and Opportunities
6.6.4 Respiratory Disorders: Geographic Segmentation
6.7 Obesity Management
6.7.1 Introduction and Market Overview
6.7.2 Historic and Forecasted Market Size (2016-2030F)
6.7.3 Key Market Trends, Growth Factors and Opportunities
6.7.4 Obesity Management: Geographic Segmentation
6.8 Neurological Disorders
6.8.1 Introduction and Market Overview
6.8.2 Historic and Forecasted Market Size (2016-2030F)
6.8.3 Key Market Trends, Growth Factors and Opportunities
6.8.4 Neurological Disorders: Geographic Segmentation
6.9 Others
6.9.1 Introduction and Market Overview
6.9.2 Historic and Forecasted Market Size (2016-2030F)
6.9.3 Key Market Trends, Growth Factors and Opportunities
6.9.4 Others: Geographic Segmentation
Chapter 7: Digital Therapeutics Market by Sales Channel
7.1 Digital Therapeutics Market Overview Snapshot and Growth Engine
7.2 Digital Therapeutics Market Overview
7.3 App Store
7.3.1 Introduction and Market Overview
7.3.2 Historic and Forecasted Market Size (2016-2030F)
7.3.3 Key Market Trends, Growth Factors and Opportunities
7.3.4 App Store: Geographic Segmentation
7.4 B2C
7.4.1 Introduction and Market Overview
7.4.2 Historic and Forecasted Market Size (2016-2030F)
7.4.3 Key Market Trends, Growth Factors and Opportunities
7.4.4 B2C: Geographic Segmentation
7.5 Others
7.5.1 Introduction and Market Overview
7.5.2 Historic and Forecasted Market Size (2016-2030F)
7.5.3 Key Market Trends, Growth Factors and Opportunities
7.5.4 Others: Geographic Segmentation
Chapter 8: Digital Therapeutics Market by End-user
8.1 Digital Therapeutics Market Overview Snapshot and Growth Engine
8.2 Digital Therapeutics Market Overview
8.3 Patients
8.3.1 Introduction and Market Overview
8.3.2 Historic and Forecasted Market Size (2016-2030F)
8.3.3 Key Market Trends, Growth Factors and Opportunities
8.3.4 Patients: Geographic Segmentation
8.4 Healthcare Providers
8.4.1 Introduction and Market Overview
8.4.2 Historic and Forecasted Market Size (2016-2030F)
8.4.3 Key Market Trends, Growth Factors and Opportunities
8.4.4 Healthcare Providers: Geographic Segmentation
8.5 Employers
8.5.1 Introduction and Market Overview
8.5.2 Historic and Forecasted Market Size (2016-2030F)
8.5.3 Key Market Trends, Growth Factors and Opportunities
8.5.4 Employers: Geographic Segmentation
8.6 Insurers/Payers
8.6.1 Introduction and Market Overview
8.6.2 Historic and Forecasted Market Size (2016-2030F)
8.6.3 Key Market Trends, Growth Factors and Opportunities
8.6.4 Insurers/Payers: Geographic Segmentation
8.7 Others
8.7.1 Introduction and Market Overview
8.7.2 Historic and Forecasted Market Size (2016-2030F)
8.7.3 Key Market Trends, Growth Factors and Opportunities
8.7.4 Others: Geographic Segmentation
Chapter 9: Company Profiles and Competitive Analysis
9.1 Competitive Landscape
9.1.1 Competitive Positioning
9.1.2 Digital Therapeutics Sales and Market Share By Players
9.1.3 Industry BCG Matrix
9.1.4 Heat Map Analysis
9.1.5 Digital Therapeutics Industry Concentration Ratio (CR5 and HHI)
9.1.6 Top 5 Digital Therapeutics Players Market Share
9.1.7 Mergers and Acquisitions
9.1.8 Business Strategies By Top Players
9.2 OMADA HEALTH INC. (US)
9.2.1 Company Overview
9.2.2 Key Executives
9.2.3 Company Snapshot
9.2.4 Operating Business Segments
9.2.5 Product Portfolio
9.2.6 Business Performance
9.2.7 Key Strategic Moves and Recent Developments
9.2.8 SWOT Analysis
9.3 RESMED (US)
9.4 PEAR THERAPEUTICS INC. (US)
9.5 SOLERA NETWORK (US)
9.6 AKILI INTERACTIVE LABS INC. (US)
9.7 BETTER THERAPEUTICS LLC (US)
9.8 BIOFOURMIS (US)
9.9 CLICK THERAPEUTICS INC. (US)
9.10 NATURALCYCLES NORDIC AB (SWEDEN)
9.11 NUVOAIR AB (SWEDEN)
9.12 WELLDOC’S BLUESTAR (US)
9.13 HAPPIFY INC. (US)
9.14 LIMBIX HEALTH INC. (US)
9.15 VOLUNTIS (US)
9.16 XEALTH (US)
9.17 BIOBEAT (ISRAEL)
9.18 KAIA HEALTH (US)
9.19 GINGER (US)
9.20 PROPELLER HEALTH (US)
9.21 HINGE HEALTH INC. (US)
9.22 OTHER MAJOR KEY PLAYERS
Chapter 10: Global Digital Therapeutics Market Analysis, Insights and Forecast, 2016-2030
10.1 Market Overview
10.2 Historic and Forecasted Market Size By Type
10.2.1 Device
10.2.2 Software
10.2.3 Hybrid
10.3 Historic and Forecasted Market Size By Application
10.3.1 Mental Health
10.3.2 Diabetes Management
10.3.3 Cardiovascular Disease
10.3.4 Respiratory Disorders
10.3.5 Obesity Management
10.3.6 Neurological Disorders
10.3.7 Others
10.4 Historic and Forecasted Market Size By Sales Channel
10.4.1 App Store
10.4.2 B2C
10.4.3 Others
10.5 Historic and Forecasted Market Size By End-user
10.5.1 Patients
10.5.2 Healthcare Providers
10.5.3 Employers
10.5.4 Insurers/Payers
10.5.5 Others
Chapter 11: North America Digital Therapeutics Market Analysis, Insights and Forecast, 2016-2030
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 Device
11.4.2 Software
11.4.3 Hybrid
11.5 Historic and Forecasted Market Size By Application
11.5.1 Mental Health
11.5.2 Diabetes Management
11.5.3 Cardiovascular Disease
11.5.4 Respiratory Disorders
11.5.5 Obesity Management
11.5.6 Neurological Disorders
11.5.7 Others
11.6 Historic and Forecasted Market Size By Sales Channel
11.6.1 App Store
11.6.2 B2C
11.6.3 Others
11.7 Historic and Forecasted Market Size By End-user
11.7.1 Patients
11.7.2 Healthcare Providers
11.7.3 Employers
11.7.4 Insurers/Payers
11.7.5 Others
11.8 Historic and Forecast Market Size by Country
11.8.1 US
11.8.2 Canada
11.8.3 Mexico
Chapter 12: Eastern Europe Digital Therapeutics Market Analysis, Insights and Forecast, 2016-2030
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 Device
12.4.2 Software
12.4.3 Hybrid
12.5 Historic and Forecasted Market Size By Application
12.5.1 Mental Health
12.5.2 Diabetes Management
12.5.3 Cardiovascular Disease
12.5.4 Respiratory Disorders
12.5.5 Obesity Management
12.5.6 Neurological Disorders
12.5.7 Others
12.6 Historic and Forecasted Market Size By Sales Channel
12.6.1 App Store
12.6.2 B2C
12.6.3 Others
12.7 Historic and Forecasted Market Size By End-user
12.7.1 Patients
12.7.2 Healthcare Providers
12.7.3 Employers
12.7.4 Insurers/Payers
12.7.5 Others
12.8 Historic and Forecast Market Size by Country
12.8.1 Bulgaria
12.8.2 The Czech Republic
12.8.3 Hungary
12.8.4 Poland
12.8.5 Romania
12.8.6 Rest of Eastern Europe
Chapter 13: Western Europe Digital Therapeutics Market Analysis, Insights and Forecast, 2016-2030
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 Device
13.4.2 Software
13.4.3 Hybrid
13.5 Historic and Forecasted Market Size By Application
13.5.1 Mental Health
13.5.2 Diabetes Management
13.5.3 Cardiovascular Disease
13.5.4 Respiratory Disorders
13.5.5 Obesity Management
13.5.6 Neurological Disorders
13.5.7 Others
13.6 Historic and Forecasted Market Size By Sales Channel
13.6.1 App Store
13.6.2 B2C
13.6.3 Others
13.7 Historic and Forecasted Market Size By End-user
13.7.1 Patients
13.7.2 Healthcare Providers
13.7.3 Employers
13.7.4 Insurers/Payers
13.7.5 Others
13.8 Historic and Forecast Market Size by Country
13.8.1 Germany
13.8.2 UK
13.8.3 France
13.8.4 Netherlands
13.8.5 Italy
13.8.6 Russia
13.8.7 Spain
13.8.8 Rest of Western Europe
Chapter 14: Asia Pacific Digital Therapeutics Market Analysis, Insights and Forecast, 2016-2030
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 Device
14.4.2 Software
14.4.3 Hybrid
14.5 Historic and Forecasted Market Size By Application
14.5.1 Mental Health
14.5.2 Diabetes Management
14.5.3 Cardiovascular Disease
14.5.4 Respiratory Disorders
14.5.5 Obesity Management
14.5.6 Neurological Disorders
14.5.7 Others
14.6 Historic and Forecasted Market Size By Sales Channel
14.6.1 App Store
14.6.2 B2C
14.6.3 Others
14.7 Historic and Forecasted Market Size By End-user
14.7.1 Patients
14.7.2 Healthcare Providers
14.7.3 Employers
14.7.4 Insurers/Payers
14.7.5 Others
14.8 Historic and Forecast Market Size by Country
14.8.1 China
14.8.2 India
14.8.3 Japan
14.8.4 South Korea
14.8.5 Malaysia
14.8.6 Thailand
14.8.7 Vietnam
14.8.8 The Philippines
14.8.9 Australia
14.8.10 New Zealand
14.8.11 Rest of APAC
Chapter 15: Middle East & Africa Digital Therapeutics Market Analysis, Insights and Forecast, 2016-2030
15.1 Key Market Trends, Growth Factors and Opportunities
15.2 Impact of Covid-19
15.3 Key Players
15.4 Key Market Trends, Growth Factors and Opportunities
15.4 Historic and Forecasted Market Size By Type
15.4.1 Device
15.4.2 Software
15.4.3 Hybrid
15.5 Historic and Forecasted Market Size By Application
15.5.1 Mental Health
15.5.2 Diabetes Management
15.5.3 Cardiovascular Disease
15.5.4 Respiratory Disorders
15.5.5 Obesity Management
15.5.6 Neurological Disorders
15.5.7 Others
15.6 Historic and Forecasted Market Size By Sales Channel
15.6.1 App Store
15.6.2 B2C
15.6.3 Others
15.7 Historic and Forecasted Market Size By End-user
15.7.1 Patients
15.7.2 Healthcare Providers
15.7.3 Employers
15.7.4 Insurers/Payers
15.7.5 Others
15.8 Historic and Forecast Market Size by Country
15.8.1 Turkey
15.8.2 Bahrain
15.8.3 Kuwait
15.8.4 Saudi Arabia
15.8.5 Qatar
15.8.6 UAE
15.8.7 Israel
15.8.8 South Africa
Chapter 16: South America Digital Therapeutics Market Analysis, Insights and Forecast, 2016-2030
16.1 Key Market Trends, Growth Factors and Opportunities
16.2 Impact of Covid-19
16.3 Key Players
16.4 Key Market Trends, Growth Factors and Opportunities
16.4 Historic and Forecasted Market Size By Type
16.4.1 Device
16.4.2 Software
16.4.3 Hybrid
16.5 Historic and Forecasted Market Size By Application
16.5.1 Mental Health
16.5.2 Diabetes Management
16.5.3 Cardiovascular Disease
16.5.4 Respiratory Disorders
16.5.5 Obesity Management
16.5.6 Neurological Disorders
16.5.7 Others
16.6 Historic and Forecasted Market Size By Sales Channel
16.6.1 App Store
16.6.2 B2C
16.6.3 Others
16.7 Historic and Forecasted Market Size By End-user
16.7.1 Patients
16.7.2 Healthcare Providers
16.7.3 Employers
16.7.4 Insurers/Payers
16.7.5 Others
16.8 Historic and Forecast Market Size by Country
16.8.1 Brazil
16.8.2 Argentina
16.8.3 Rest of SA
Chapter 17 Investment Analysis
Chapter 18 Analyst Viewpoint and Conclusion